Small-molecule therapies have gained considerable attention as a promising approach to modifying the underlying mechanisms of AD, particularly by targeting specific molecular pathways involved in amyloid plaque formation, tau phosphorylation, and neuroinflammation. This evidence concerns the gene MAPT and Alzheimer disease.